Please assess the completion status of the following clinical trial:

Trial Title: 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults aged ≥ 40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure~* Co-operative outpatients with a diagnosis of COPD (moderate to severe as classified by the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) Guidelines, 2005) and:~  * Smoking history of at least 20 pack years~ * Post-bronchodilator FEV1 \< 80% and ≥ 30% of the predicted normal value.~ * Post-bronchodilator FEV1/FVC \< 70% (Post refers to within 30 min of inhalation of 400 µg of salbutamol)~Exclusion Criteria:~* Pregnant or lactating females~* Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period~* Patients requiring long term oxygen therapy (\> 15 h a day)~* Patients who have had a respiratory tract infection 6 weeks prior to V1 (with further criteria)~* Patients with concomitant pulmonary disease, pulmonary tuberculosis, or clinically significant bronchiectasis~* Patients with a history of asthma (with further criteria)~* Patients with Type I or uncontrolled Type II diabetes~* Patients with contraindications for tiotropium~* Patients who have clinically relevant laboratory abnormalities or a clinically significant abnormality~* Any patient with active cancer or a history of cancer with less than 5 years disease free survival time~* Patients with a history of long QT syndrome or whose QTc interval is prolonged~* Patients with a hypersensitivity to any of the study drugs or drugs with similar chemical structures~* Patients who have had treatment with the investigational drug (with further criteria)~* Patients who have had live attenuated vaccinations within 30 days prior to visit 1, or during run-in period~* Patients with known history of non compliance to medication~* Patients unable to satisfactorily use a dry powder inhaler device or perform spirometry measurements~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 150 µg (Continued Into Stage 2) (Type: EXPERIMENTAL): In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.
- Indacaterol 300 µg (Continued Into Stage 2) (Type: EXPERIMENTAL): In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.
- Tiotropium 18 µg (Continued Into Stage 2) (Type: ACTIVE_COMPARATOR): Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.
- Placebo (Continued Into Stage 2) (Type: PLACEBO_COMPARATOR): In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.
- Indacaterol 75 µg (Not Continued into Stage 2) (Type: EXPERIMENTAL): In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.
- Indacaterol 600 µg (Not Continued Into Stage 2) (Type: EXPERIMENTAL): In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.
- Formoterol 12 µg (Not Continued Into Stage 2) (Type: ACTIVE_COMPARATOR): In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study.

Based on this trial design, predict the completion outcome and termination type (if applicable).